These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 19467895

  • 1. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC, Sanchez LM, Briones E, Ramirez TJ, Castillo H, Rivera LG, Vazquez CA, Rodriguez-Padilla C, Holodniy M.
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [Abstract] [Full Text] [Related]

  • 2. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
    Foli A, Maserati R, Barasolo G, Castelli F, Tomasoni L, Migliorino M, Maggiolo F, Pan A, Paolucci S, Scudeller L, Tinelli C, D'Aquila R, Lisziewicz J, Lori F.
    Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
    [Abstract] [Full Text] [Related]

  • 3. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
    Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Battegay M, Furrer H, Vernazza P, Bernasconi E, Telenti A, Weber R, Leduc D, Yerly S, Price D, Dawson SJ, Klimkait T, Perneger TV, McLean A, Clotet B, Gatell JM, Perrin L, Plana M, Phillips R, Hirschel B, Swiss HIV Cohort Study.
    Arch Intern Med; 2003 May 26; 163(10):1220-6. PubMed ID: 12767960
    [Abstract] [Full Text] [Related]

  • 4. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P, Srasuebkul P, Hassink E, Mahanontharit A, Samor T, Ruxrungtham K, Lange J, Cooper D, Phanuphak P.
    HIV Med; 2005 Mar 26; 6(2):122-8. PubMed ID: 15807718
    [Abstract] [Full Text] [Related]

  • 5. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A, Martinez E, Milinkovic A, Mora B, Mallolas J, Blanco JL, Larrousse M, Laguno M, Gallart T, Plana M, Gatell JM, Garcia F.
    J Antimicrob Chemother; 2009 Jan 26; 63(1):184-8. PubMed ID: 19001447
    [Abstract] [Full Text] [Related]

  • 6. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.
    AIDS; 2008 Aug 20; 22(13):1583-8. PubMed ID: 18670217
    [Abstract] [Full Text] [Related]

  • 8. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
    Oxenius A, Price DA, Günthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, García F, Hirschel B, McLean A, Phillips RE.
    Proc Natl Acad Sci U S A; 2002 Oct 15; 99(21):13747-52. PubMed ID: 12370434
    [Abstract] [Full Text] [Related]

  • 9. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
    Resino S, M Bellón J, Gurbindo D, Tomás Ramos J, Antonio León J, Jose Mellado M, Angeles Muñoz-Fernández M.
    Clin Infect Dis; 2003 Nov 01; 37(9):1216-25. PubMed ID: 14557967
    [Abstract] [Full Text] [Related]

  • 10. Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children.
    Palacios-Saucedo GC, Rivera-Morales LG, Vázquez-Guillén JM, Sánchez LM, Ramírez TJ, Briones E, Ortiz-López R, Vázquez CA, Rodríguez-Padilla C.
    Curr HIV Res; 2011 Apr 01; 9(3):154-9. PubMed ID: 21457133
    [Abstract] [Full Text] [Related]

  • 11. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
    Launay O, Duval X, Dalban C, Descamps D, Peytavin G, Certain A, Mouajjah S, Ralaimazava P, Verdon R, Costagliola D, Clavel F, ANRS 109 VISTA Study Group.
    Antivir Ther; 2006 Apr 01; 11(7):889-99. PubMed ID: 17302251
    [Abstract] [Full Text] [Related]

  • 12. Successful simplification of HAART in patients with acute primary HIV infection.
    Sinicco A, Bonora S, Arnaudo I, Zeme DA, Audagnotto S, Raiteri R, Di Perri G.
    J Biol Regul Homeost Agents; 2002 Apr 01; 16(1):69-72. PubMed ID: 12003178
    [Abstract] [Full Text] [Related]

  • 13. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J.
    J Infect; 2007 Feb 01; 54(2):159-66. PubMed ID: 16690132
    [Abstract] [Full Text] [Related]

  • 14. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
    Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K.
    Clin Infect Dis; 2005 Mar 01; 40(5):728-34. PubMed ID: 15714420
    [Abstract] [Full Text] [Related]

  • 15. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S.
    Antivir Ther; 2008 Mar 01; 13(7):927-36. PubMed ID: 19043927
    [Abstract] [Full Text] [Related]

  • 16. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.
    Eur J Med Res; 2002 Jul 24; 7(7):330-4. PubMed ID: 12176683
    [Abstract] [Full Text] [Related]

  • 17. Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
    Carcelain G, Tubiana R, Samri A, Calvez V, Delaugerre C, Agut H, Katlama C, Autran B.
    J Virol; 2001 Jan 24; 75(1):234-41. PubMed ID: 11119593
    [Abstract] [Full Text] [Related]

  • 18. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Jan 24; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.
    Jayaweera DT, Kolber MA, Brill M, Tanner T, Campo R, Rodriguez A, Chu HM, Garg V.
    HIV Med; 2004 Sep 24; 5(5):364-70. PubMed ID: 15369512
    [Abstract] [Full Text] [Related]

  • 20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Sep 24; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.